Hims & Hers vs NiceRx
Two GLP-1 desks, one scoreboard. We put Hims & Hers and NiceRx head-to-head on the published Brief Score — the same six factors, scored the same way.
Hims & Hers
FDA warning letter, September 2025 — issued to Hims & Hers Health, Inc. dba Hims. See the FDA's warning letter database.
NiceRx
The verdict
NiceRx takes this head-to-head.
NiceRx scores 86 to 85 on our six-factor Brief Score — An established medication-access brand, now LegitScript-certified and nationwide on both molecules.
That doesn't make Hims & Hers a bad call — it's best for readers who want a familiar, app-driven consumer brand and nationwide access. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Hims & Hers | NiceRx | |
|---|---|---|
| Brief Score | 85/100 (B) | 86/100 (B) |
| Semaglutide | $199/mo | $199/mo |
| Tirzepatide | Not disclosed | $299/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Risingprice rising | Stableprice stable |
Hims & Hers: App-first reach is nationwide, but compounded supply has drawn industry-wide scrutiny.
NiceRx: $199 sema / $299 tirz nationwide; LegitScript-certified, established operator.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.